Solana’s recent sell-off from its seven-month high seems to have stopped at technical support with renewed upside possibly being on the cards.
Solana's Elliott wave abc correction from its $209.88 seven-month high seems to have ended at $175.81, right at its $175.79-to-$173.48 support zone. It contains the mid-to-25 July and 11 August lows.
While this support area holds, the 28 July and 17 August highs at $195.17-to-$195.92 are in focus. If bettered, the $206.32 July peak and $209.88 current August high, together with the March 2024 high at $210.18 might be targeted.
Were Solana to resume its recent descent and fall through its $175.79-to-$173.48 support area on a daily chart closing basis, a medium-term bearish trend reversal may ensue.
In this scenario the June-to-August support line, currently at $169.67, might be revisited as well as the $159.54-to-$155.82 support area. It consists of several daily chart highs and lows since the 19 May and includes the 200-day simple moving average (SMA) and early August low.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.